HRTX News and Press, Heron Therapeutics Inc.

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....

2024-07-02 09:18:19 ET More on Heron Therapeutics Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves Seeking Alpha’s Quant Rating on Heron Therapeutics Historical earnings data for Heron Therapeutics Read the full artic...

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...

2024-06-27 17:42:31 ET Summary Heron Therapeutics, Inc. stock has seen a 170% gain since the last cautionary article in July 2023. Heron's future depends on the success of unproven new products rather than on its traditional lineup. Near-term financing with likely dilution is ...

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...

2024-05-27 10:45:03 ET Heron Therapeutics Inc (HRTX) HRTX is trading UP for the last 5 days, and it at trading at $2.86 with volume of 6,916,602 and a one day change of $0.02 (0.53%). Heron Therapeutics Inc has a 52-week low of 0.50 and a 52-week high of $3.22. The business's 50-day...

2024-05-17 10:45:03 ET Alphabet Inc (GOOGL) GOOGL is trading UP for the last 5 days, and it at trading at $171.27 with volume of 23,281,227 and a one day change of $3.22 (1.91%). Alphabet Inc has a 52-week low of 105.16 and a 52-week high of $174.71. The business's 50-day moving ave...

2024-05-07 14:38:07 ET Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Conference Call May 07, 2024 08:30 AM ET Company Participants Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President and Chief Financial Officer William Forbes - Execut...

2024-05-07 08:02:30 ET More on Heron Therapeutics Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript Heron Th...

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates PR Newswire Net Product Sales of $34.7 million , which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02) , which decreased...